Weekly Recap | Kodiak Sciences +11.97%, closing in on record highs

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

Kodiak Sciences (KOD) gained 11.97% on the week, closing at $111.19 and outperforming the S&P 500 by about 9.46 percentage points. The stock opened Monday at $101.72 and pushed higher through the week, hitting an intraday high of $112.79 on Friday before settling at $111.19. Weekly amplitude was 13.01%, while average daily volume of 788k shares ran about 17.7% below its median, suggesting a relatively light-volume rally. The close sits well above both the 20-day moving average of $97.61 and the 60-day line at $70.26, and far off the 60-day range low of $29.81.

Key Events

Company news clustered in the back half of the week. The stock surged over 8% intraday on Monday and set fresh 52-week highs in after-hours trading on Tuesday and Wednesday. On Wednesday, Kodiak announced it will present at three upcoming investor conferences. Before Friday’s open, the company reported fiscal Q3 results: revenue of $0 and GAAP EPS of -$1.05, beating estimates by $0.01, though net loss widened as R&D expenses rose. On Saturday, UBS maintained its buy rating and lifted its price target to $150 from $120, while commentary asked whether Phase 3 eye drug results have shifted the investment narrative. There were no material filings during the week.

Analyst Ratings

Seven brokers cover KOD, with 5 at buy, 1 at overweight, and 1 at hold; no one is at underweight or sell. The consensus rating is strong buy, and the consensus target of $129.5 sits about 16.5% above the latest close. Targets range from $103 to $150, with most of the dispersion on the upside. Within the biotech industry, KOD ranks 240th out of 514 names by rating, placing it near the middle of the group.

The Week Ahead

Macro data dominates next week: the New York Fed manufacturing index lands on 16 November, followed by retail sales, industrial production, and the NAHB housing market index on 17 November. Company-specific catalysts are thin, with attention likely to stay on the UBS target hike and on how the Phase 3 eye drug data continues to be interpreted, plus any details from the investor conferences.

In Short

KOD advanced this week against a backdrop of results and a broker target hike. The sell-side stance is positive, with the consensus target above the spot price, while the company remains pre-revenue with a widening net loss. Valuation is stretched by conventional measures—roughly 556x book and a negative P/E—and the latest session showed large-lot money as a net seller while smaller lots were net buyers. The key question going forward is whether Phase 3 data can support the current repricing and narrow the wide target spread.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings